Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

625 results

• (EPOC)Independent statistical analysis of Evaluation of Point-of-Care (EPOC) for COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05227404).Phase NAResults postedn = 330NCT05227404
• 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 109NCT00771953
• 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 405NCT01794741
• 32543Independent statistical analysis of Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01027806).Phase 4Results postedn = 64NCT01027806
• 4 Pillars Toolkit for Adolescent Vaccination: Complete Statistical AnalysisIndependent statistical analysis of 4 Pillars Toolkit for Adolescent Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02165722).Phase NAResults postedn = 22NCT02165722
• 65plusIndependent statistical analysis of Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 271NCT00976456
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.: Complete Statistical AnalysisIndependent statistical analysis of A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD…Phase 3Results postedn = 1,042NCT01727141
• A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate…Phase 3Results postedn = 1,031NCT01053988
• A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 64NCT02109172
• A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 550NCT00682643
• A Clinical Trial of CSL’s 2010/2011 Formulation of Enzira® in a Healthy Adult Population: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 120NCT01113580
• A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 47NCT02879617
• A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056): Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056): primary endpoint results, effect estimate…Phase 2/3Results postedn = 253NCT00473889
• A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions: Complete Statistical AnalysisIndependent statistical analysis of A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo…Phase 3Results postedn = 333NCT03843541
• A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters: Complete Statistical AnalysisIndependent statistical analysis of A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 94NCT01196533
• A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough: Complete Statistical AnalysisIndependent statistical analysis of A Comparison of Desflurane vs. Sevoflurane and the Time to Awakening and the Incidence and Severity of Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase NAResults postedn = 85NCT01202162
• A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of A Comprehensive Care Programme for Patients With Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 180NCT01108835
• A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1Results postedn = 28NCT04661839
• A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects…Phase 3Results postedn = 207NCT02014480
• A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine: Complete Statistical AnalysisIndependent statistical analysis of A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04669691).Phase 2Results postedn = 420NCT04669691
• A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients…Phase 4Results postedn = 30NCT02153489
• A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D): Complete Statistical AnalysisIndependent statistical analysis of A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D): primary endpoint results, effect estimate with…Phase 1/2Results postedn = 6NCT01976091
• A Long-term Safety Study of QMF149 in Japanese Participants With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Long-term Safety Study of QMF149 in Japanese Participants With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 51NCT03100500
• A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold: Complete Statistical AnalysisIndependent statistical analysis of A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 146NCT01883453
• A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 239NCT02233803
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 960NCT01309737
• A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1): Complete Statistical AnalysisIndependent statistical analysis of A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive…Phase 3Results postedn = 272NCT00604500
• A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 295NCT01544348
• A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 122NCT03678688
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected…Phase 1/2Results postedn = 222NCT03829501
• A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 77NCT03911713
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 388NCT05412030
• A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 11NCT00590720
• A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants:…Phase 3Results postedn = 1,574NCT04713553
• A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic…Phase 3Results postedn = 1,101NCT01241591
• A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans: Complete Statistical AnalysisIndependent statistical analysis of A Pilot and Feasibility Study of Mobile-Based Asthma Action Plans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01514760).Phase NAResults postedn = 22NCT01514760
• A Pilot Study of Acupuncture Treatment for Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of A Pilot Study of Acupuncture Treatment for Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00797732).Phase NAResults postedn = 42NCT00797732
• A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age…Phase NAResults postedn = 2,409NCT01995175
• A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.: Complete Statistical AnalysisIndependent statistical analysis of A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.: primary endpoint results, effect…Phase 2Results postedn = 599NCT00603382
• A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension: primary endpoint results,…Phase 2Results postedn = 48NCT00853112
• A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 100NCT02578914
• A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma: primary endpoint results,…Phase 3Results postedn = 1,113NCT02031640
• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment: primary endpoint results, effect estimate with…Phase 2Results postedn = 161NCT01610336
• A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 12NCT04264156
• A Safety and Efficacy Study of Tralokinumab in Adults With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Efficacy Study of Tralokinumab in Adults With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 689NCT01402986
• A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 146NCT00515034
• A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma: Complete Statistical AnalysisIndependent statistical analysis of A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 197NCT00809757
• A Stepped Care Intervention to Reduce Disparities in Mental Health Services Among Cancer Patients and Caregivers: Complete Statistical AnalysisIndependent statistical analysis of A Stepped Care Intervention to Reduce Disparities in Mental Health Services Among Cancer Patients and Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 535NCT03016403
• A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease…Phase NAResults postedn = 11,296NCT03979807
• A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 969NCT01808092

← All therapeutic areas